Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment

BACKGROUND: Antibody-drug conjugates (ADCs) have been the preferred regimens for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) after trastuzumab. Unfortunately, there is little data showing which ADCs should be chosen for those patients whose treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Chenchen, Li, Feng, Yuan, Yang, Zhang, Huiqiang, Bian, Li, Zhang, Shaohua, Wang, Tao, Li, Jianbin, Jiang, Zefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546815/
https://www.ncbi.nlm.nih.gov/pubmed/37218076
http://dx.doi.org/10.1093/oncolo/oyad127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546815/
https://www.ncbi.nlm.nih.gov/pubmed/37218076
http://dx.doi.org/10.1093/oncolo/oyad127

Ejemplares similares